Prof Eliza Hawkes
Honorary Professorial Fellow
Department of Medicine
332 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
DOI: 10.1200/JCO-26-018002026
Journal article
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
DOI: 10.1182/bloodadvances.20260200122026
Journal article
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
DOI: 10.1002/hem3.704432026
Journal article
Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches.
DOI: 10.1038/s41698-026-01604-w2026
Journal article
Low lymphoma macrophage infiltration predicts poor outcomes in R-CHOP- but not Pola-R-CHP-treated patients with DLBCL
DOI: 10.1016/j.bneo.2026.1002642026
Journal article
Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice
DOI: 10.1111/bjh.705502026
Journal article
Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy
DOI: 10.1182/blood.2026033090
RECENT SCHOLARLY WORKS
2026
Journal article
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.
DOI: 10.1200/jco.2026.44.16_suppl.tps71022026
Journal article
Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study
DOI: 10.1111/bjh.704682026
Journal article
Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
DOI: 10.1002/jha2.70212